Journal Article

Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialyis patients

S. Pol, V. Thiers, F. Carnot, B. Zins, R. Roméo, P. Berthelot and C. Bréchot

in Nephrology Dialysis Transplantation

Volume 11, issue supp4, pages 58-61
Published in print January 1996 | ISSN: 0931-0509
Published online January 1996 | e-ISSN: 1460-2385 | DOI: https://dx.doi.org/10.1093/ndt/11.supp4.58
Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialyis patients

Show Summary Details

Preview

Twenty-five per cent of haemodialysed patients carry anti-HCV antibodies; these antibodies are associated with detectable viraemia in 85% and chronic hepatitis in 90% of subjects, despite normal transaminases in more than half of them. This underlines the importance of antiviral therapy We evaluated the tolerance and effectiveness of a classic interferon (IFN) treatment (3 MU three times a week for 6 months, subcutaneously) in 19 haemodialysis patients presenting with anti-HCV antibodies and chronic (n=16) or acute (n=3) hepatitis. Thirteen of those 19 patients had elevated transaminases. Viraemia C was detected by genome amplification (PCR) and by the bDNA test before and after interferon therapy as well as 6 months at least after the end of INF treatment. Response (defined as liver enzyme normalization) was noted in 11 (84.6%) of the 13 patients with elevated transaminases; at the end of follow-up, six exhibited long-term response and five had relapsed, HCV-RNA was detected in 15 of the 19 patients before IFN therapy and remained positive in 7/15 initially viraemic patients at the end of treatment. Hepatitis C RNA was detected at the last follow-up visit (mean follow-up duration 18±9 months) in 12 of the 15 initially viraemic patients. Liver histology was improved in most patients, regardless of their biological response. One patient could not complete the 6-month course because of clinical and haematological adverse events. In the six patients with strictly normal transaminases, HCV RNA was detectable in 4/6 patients before treatment, in 2/4 viraemic patients at the end of treatment, and in 4/4 at the last follow-up visit. All pathological signs disappeared in four of the five patients who had no detectable HCV-RNA before IFN therapy. To conclude: (i) interferon-α exhibits satisfactory effectiveness and tolerance in haemodialysed patients; (ii) HCV replication recurs in most of these patients despite histological improvement; (iii) interferon-α can be effective even in patients with chronic hepatitis and no detectable HCV-RNA.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.